Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Lombard Odier Stays Overweight on U.S. Stocks -- Market Talk

Lombard Odier Stays Overweight on U.S. Stocks -- Market Talk

Dow JonesDow Jones2026/11/04 09:20

0920 GMT - U.S. stocks and dollar should be supported by relative U.S. strength and higher interest rate differentials following the midterm elections, Lombard Odier's Michael Strobaek says in commentary. "A Democratic sweep should reinforce Fed independence, as Senate approval of new board appointments would provide an institutional check, supporting the dollar," the global chief investment officer says. Strobaek adds that U.S. equities tend to rise after midterm elections. Valuations already price in many uncertainties, while earnings growth remains strongest among developed markets, he says. The bank remains overweight on U.S. stocks. (tracy.qu@wsj.com)

(END) Dow Jones Newswires

November 04, 2026 04:20 ET (09:20 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss